Avenue Therapeutics News and Activities

Avenue Therapeutics is owned by Fortress Biotech.

Fortress Biotech is a company listed under the stock ticker FBIO (US).

Fortress Biotech has 4 subsidiaries including Avenue Therapeutics, Checkpoint Therapeutics and Journey Medical Corp.

They are in:

• Biotechnology80%
• Pharmaceuticals20%

View the org chart displaying its 7 main executives

Most searched biographies at Avenue Therapeutics

• Alexandra Maclean, Chief Executive Officer
• Jay Kranzler, Chairman of the Board
• Neil Herskowitz, Director

Popular executive movements at Fortress Biotech

• George Avgerinos, Senior Vice President, Biologics Operations, has left the company  (posted on November 28 2025).

Create your alert
to follow the executive moves at Avenue Therapeutics.

Fortress Biotech has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Avenue Therapeutics

• Press Releases | Avenue Therapeutics
• Email Alerts
• Press Releases | Avenue Therapeutics
• https://avenuetx.com/wp-content/uploads/2017/06/Avenue-Therapeutics-Inc.-Pricing-Press-Release-June-2017_FINAL.pdf
• Press Releases | Avenue Therapeutics

Social media about Avenue Therapeutics

• Avenue Therapeutics on Wikipedia, Google News & Yahoo Finance
• Avenue Therapeutics on LinkedIn, X (Twitter) & YouTube